Study Design of a Phase 3, Randomized, Double-Blind Study of Ublituximab Versus Fingolimod in Children and Adolescents with Relapsing Multiple Sclerosis: ULTIMATE KIDS II By Sheena Cruz / 02/06/2026
Real-World Infusion Experience with Ublituximab in ENABLE, the Phase 4 Observational Study By admin / 02/06/2026
Study Design of a Phase 2 Ublituximab Dose-Confirmation Study in Children and Adolescents with Relapsing Multiple Sclerosis: ULTIMATE KIDS I By admin / 02/06/2026
Safety and Tolerability of 30-minute Ublituximab Infusions: Updates from the ENHANCE Study By admin / 02/27/2025
The Design of a Study to Evaluate Fc Biology and Genetic Diversity in Multiple Sclerosis By admin / 02/27/2025
Evaluating the Maintenance of Efficacy and Tolerability of Transitioning from IV Anti-CD20 Therapy to Ublituximab: ENHANCE Study Interim Data By admin / 02/29/2024
MS Relapse Redefined: Addressing the Radiological/Pseudoexacerbation Paradox with High Efficacy Therapy in the ULTIMATE I and II Trials By admin / 02/29/2024
Onset and Maintenance of No Evidence of Disease Activity With Ublituximab: Analyses of the Phase 3 ULTIMATE I and II Studies in Participants With Relapsing Multiple Sclerosis By admin / 02/23/2023
Early, Transient Shift in Hematologic Parameters Observed With Ublituximab in the ULTIMATE I and II Phase 3 Studies By admin / 02/23/2023
Reduction in T1 Hypointense Lesions with Ublituximab vs Teriflunomide in the Phase 3 ULTIMATE I & II Studies in Relapsing Multiple Sclerosis By admin / 02/24/2022
